<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062152</url>
  </required_header>
  <id_info>
    <org_study_id>TLK199.1104</org_study_id>
    <nct_id>NCT01062152</nct_id>
  </id_info>
  <brief_title>Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Telik</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Telik</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multicenter Phase 1 dose escalation study evaluating five doses of&#xD;
      ezatiostat in combination with lenalidomide in patients with non-del(5q) low to intermediate&#xD;
      1 risk MDS. The HI-E, HI-N, HI-P rates [by International Working Group (IWG) 2006 criteria]&#xD;
      and safety of each treatment group will be evaluated to select the optimal dose of ezatiostat&#xD;
      in combination with lenalidomide for future studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the maximum tolerated dose (MTD) of ezatiostat in combination with lenalidomide</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the safety of ezatiostat in combination with lenalidomide</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the efficacy of ezatiosate in combination wiht lenalidomide in patients with non-del(5q) low to intermediate-1 risk of MDS</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Improvement-Erythroid (HI-E) rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Improvement-Neutrophil (HI-N) rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Improvement-Platelet (HI-P) rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Revlimid® in Combination with Telintra ®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide (Revlimid®) followed by Telintra® until MDS progression or lack of efficacy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezatiostat Hydrochloride</intervention_name>
    <description>Starting dose 2000 mg orally in divided doses twice daily (1000 mg in AM &amp; 1000 mg in PM) x 21 days with one week off therapy in a 4-week cycle.</description>
    <arm_group_label>Revlimid® in Combination with Telintra ®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide (Revlimid®)</intervention_name>
    <description>10 mg orally per day in one AM dose x 21 days with one week off therapy in a 4-week cycle.</description>
    <arm_group_label>Revlimid® in Combination with Telintra ®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of primary or de novo MDS using WHO classification&#xD;
&#xD;
          -  Non-del(5q) low or Intermediate-1risk MDS&#xD;
&#xD;
          -  ECOG performance status of 0-1&#xD;
&#xD;
          -  Documented significant cytopenia for at least 2 months&#xD;
&#xD;
          -  Must have discontinued growth factors (EPO, G-CSF, GM-CSF) for at least 21 days prior&#xD;
             to study entry&#xD;
&#xD;
          -  All study participants must be registered into the mandatory RevAssist® program and be&#xD;
             willing and able to comply with the requirements of RevAssist®&#xD;
&#xD;
          -  Females of childbearing potential should have two negative serum pregnancy tests with&#xD;
             a sensitivity of at least 50 mIU/mL. The first test should be performed within 10-14&#xD;
             days, and the second test within 24 hours of prescribing lenalidomide (prescriptions&#xD;
             must be filled within seven days)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to Telintra™ (intravenous or oral)&#xD;
&#xD;
          -  Known prior therapy with or hypersensitivity to thalidomide or lenalidomide&#xD;
&#xD;
          -  Prior allogenic bone marrow transplant for MDS&#xD;
&#xD;
          -  History or prior malignancy&#xD;
&#xD;
               -  Except for treated carcinoma of uterine cervix, basal cell or squamous cell skin&#xD;
                  cancer, or other cancers (e.g. breast, prostate) for which patient has been&#xD;
                  disease-free for at least 3 years.&#xD;
&#xD;
          -  MDS evolving from:&#xD;
&#xD;
               -  A pre-existing myeloproliferative disorder&#xD;
&#xD;
               -  An autoimmune disease&#xD;
&#xD;
               -  Secondary to prior treatment with radiation or chemotherapy&#xD;
&#xD;
          -  History of MDS IPSS score&gt;1.0&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Leptomeningeal or leukemic meningitis&#xD;
&#xD;
          -  Prior treatment with DNA methyltransferase inhibitors (DMTI) [e.g., azacitadine,&#xD;
             decitabine, etc.]&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Brown, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Telik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Chicago Cardinal Benardin Cancer Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MDAnderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematology</keyword>
  <keyword>MDS</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Low risk MDS</keyword>
  <keyword>Patients with non-deletion(5q)</keyword>
  <keyword>Non-deletion 5q</keyword>
  <keyword>Non del(5q)</keyword>
  <keyword>Revlimid</keyword>
  <keyword>lenalidomide</keyword>
  <keyword>Telintra</keyword>
  <keyword>ezatiostat hydrochloride</keyword>
  <keyword>ezatiostat</keyword>
  <keyword>TLK199</keyword>
  <keyword>Glutathione</keyword>
  <keyword>Glutathione analog</keyword>
  <keyword>Glutathione Transferase</keyword>
  <keyword>Glutathione Transferase inhibitor</keyword>
  <keyword>Glutathione Transferase P1-1 inhibitor</keyword>
  <keyword>GSTp1-1 inhibitor</keyword>
  <keyword>Apoptosis</keyword>
  <keyword>Differentiation</keyword>
  <keyword>Enzyme inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

